The biotech week kicked off with a bang, not because of any macro factors like a new Federal Reserve program of monetary stimulus, or economic data emanating from Europe. BioSante
Two other biotechs, though, had big moves today for company-specific reasons. Let's dive into each story and highlight key investor takeaways.
Not that it's any consolation for long-term holders, as shares traded at about $15 as recently as last summer. The company remains wildly unprofitable, but its more accurate, albeit slower, technology gives BGI not only a U.S. presence but also leverage against Illumina
What is the opposite of disappointing? Hitting an all-time high. Investors in Jazz Pharmaceuticals
Investors are attracted to biotechs like Jazz since they hold the allure of substantial short-term gains. But there's more than one approach to building long-term wealth and retiring well. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some winning wealth-building strategies. Click here to keep reading.
David Williamson holds no position in any company mentioned. Check out his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Illumina. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days. The Motley Fool has a disclosure policy.